Gianpaolo Pisano, Piergiorgio Spaggiari, Jean Pierre Pintucci, Massimo Blanco, Caterina Tribbia, Chiara Liberati, Teodosio De Bonis, Giorgia Grappeggia, Pier Mario Biava, Use of Stem Cell Growth and Differentiation Factors (Scdsf) in Central Vertigo, Journal of Otolaryngology Advances, Volume 2, Issue 4, 2026, Pages 3-20, ISSN 2379-8572, https://doi.org/10.14302/issn.2379-8572.joa-26-6454.
(https://ijn-medicalarticles.info/otolaryngology-advances/article/use-of-stem-cell-growth-and-differentiation-factors-scdsf-in-central-vertigo-2399)
Abstract: The clinical use of SCDSF factors in neuro-degenerative pathologies offers a potential therapeutic opportunity. Our observational study aims to evaluate its efficacy in patients affected by Central Vertigo1. A case series divided into two subgroups, all affected by non-migrainous central vertigo, was selectively subjected, in epigenetic terms versus the genome, to the administration of SCDSF with a regenerative action or to the administration of a reprogramming and then regenerative action. The cohort was divided into two groups due to the emergence of a resistance to the action of neuro-regenerative SCDSF when administered individually according to consolidated therapy schemes. To recover efficacy, it became necessary to first administer reprogramming SCDSF and only subsequently the neuro-regenerative SCDSF. The observation that a therapeutic barrier was overcome during the study—a barrier to the action of neuro-regenerative SCDSF, only when preceded by the administration of reprogramming SCDSF versus the genome—highlighted a deeper mechanism. A targeted action aimed at recovering the functionality of the epigenetic code was employed to counteract environmental epi-genotoxicity.
Keywords: stem cell; ataxic vertigo; central vertigo; neurodegenerative diseases; stem cell differentiation factors; epigenetic code; morphogenetic code; genotoxicity; epi-genotoxicity; CVD; SCDSF; CSCs